Chemotherapeutic Management of Hemangiosarcoma in Canines – An Update

Khan Sharun
Additional contact information
Khan Sharun: Division of Surgery, ICAR-Indian Veterinary Research Institute, India

Cancer Therapy & Oncology International Journal, 2019, vol. 14, issue 1, 6-8

Abstract: Hemangiosarcoma is a malignant vascular endothelial tumor affecting canines. It commonly affects older animals and is also characterized by certain breed predilection. Spleen is the most commonly affected organ in canines but skin associated hemangiosarcomas are less frequent. Management of malignant tumors like hemangiosarcoma should be based on multimodal therapy that combines different techniques like surgical excision, chemotherapy, radiation therapy, and immunotherapy. Even though several chemotherapeutic agents are used alone or as in combinations, it was ineffective in producing a desirable increase in the survival period. Newer agents like Paclitaxel and Resveratrol was found to be effective against hemangiosarcoma cell lines in-vitro. But further studies are required for evaluating the in-vivo effects of such chemotherapeutic agents. Further research should be directed to identify effective chemotherapeutic agents like Paclitaxel and Resveratrol that can be used to manage canine hemangiosarcoma clinically without any side effects.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555878.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555878.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:14:y:2019:i:1:p:6-8

DOI: 10.19080/CTOIJ.2019.14.555878

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().